-
Mashup Score: 0
According to Jason Luke, MD, FACP, there is still room to improve response rates in CSCC treatment, but there is excitement surrounding future of treatment outcomes.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Objective response data from the CK-301-101 trial supports cosibelimab’s approval by the FDA, according to Jason J. Luke, MD, FACP.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Objective response data from the CK-301-101 trial supports cosibelimab’s approval by the FDA, according to Jason J. Luke, MD, FACP. #melsm | @jasonlukemd https://t.co/W8KBbo9MJf
-
-
Mashup Score: 0FDA Assigns BTD and Receives BLA for RP1 Combo in Advanced Melanoma - 1 month(s) ago
Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
A BLA under the Accelerated Approval pathway has been filed to the FDA for vusolimogene oderparepvec plus nivolumab for the treatment of patients with advanced melanoma who were previously administered an anti–PD-1 regimen. #melsm https://t.co/tGAiMrcZ1E
-
-
Mashup Score: 1
Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Treatment with IMA203, an investigational T-cell therapy targeting preferentially expressed antigen in melanoma, demonstrated clinical activity among a small cohort of patients with previously treated metastatic melanoma. #melsm https://t.co/weuDzLYa8D
-
-
Mashup Score: 2
During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab + nivolumab and nivolumab/relatlimab in advanced melanoma. #melsm @ATarhiniMDPhD @MoffittResearch @MoffittNews https://t.co/WJ7M2f4aLc
-
-
Mashup Score: 0
During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the 2024 update to the RELATIVITY-047 trial in advanced melanoma in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Ahmad Tarhini, MD, PhD, discussed the 2024 update to the RELATIVITY-047 trial in advanced melanoma. #melsm | @ATarhiniMDPhD @MoffittResearch @MoffittNews https://t.co/3X77LJOMe0
-
-
Mashup Score: 0
Support for the planned biologics license application comes from data showing a 32.9% response rate with RP1 plus nivolumab for melanoma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The FDA held a successful pre-BLA meeting for vusolimogene oderparepvec in combination with nivolumab for the treatment of anti–PD-1–failed melanoma, supporting an accelerated approval pathway in the second half of 2024. #melsm https://t.co/9UsWO5Ez2q
-
-
Mashup Score: 0
Support for the planned biologics license application comes from data showing a 32.9% response rate with RP1 plus nivolumab for melanoma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The FDA held a successful pre-BLA meeting for vusolimogene oderparepvec in combination with nivolumab for the treatment of anti–PD-1–failed melanoma, supporting an accelerated approval pathway in the second half of 2024. #melsm https://t.co/9UsWO5Ez2q
-
-
Mashup Score: 2
The FDA has granted fast track designation to IBI363 for unresectable advanced or metastatic melanoma after progression on at least 1 line of therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The @US_FDA has granted fast track designation to IBI363 for pts w/ unresectable locally advanced or metastatic melanoma, excluding choroidal melanoma, that has progressed after 1+ prior lines of systemic therapy, including a PD-1/PD-L1 inhibitor. #melsm https://t.co/ALE2kxrpUp https://t.co/8xgimbqw4M
-
-
Mashup Score: 2
The FDA has granted fast track designation to IBI363 for unresectable advanced or metastatic melanoma after progression on at least 1 line of therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The @US_FDA has granted fast track designation to IBI363 for pts w/ unresectable locally advanced or metastatic melanoma, excluding choroidal melanoma, that has progressed after 1+ prior lines of systemic therapy, including a PD-1/PD-L1 inhibitor. #melsm https://t.co/ALE2kxrpUp https://t.co/8xgimbqw4M
-
According to Jason Luke, MD, FACP, there is still room to improve response rates in CSCC treatment, but there is excitement surrounding future of treatment outcomes. #melsm | @jasonlukemd https://t.co/3fTUEmZt2q